The U.S. Membranous Nephropathy Market is expected to grow with the CAGR of 5.0% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/us-membranous-nephropathy-market
The U.S. membranous nephropathy market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in the U.S. membranous nephropathy market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition and agreement into the membranous nephropathy market. This has helped companies to maximize the sales with enhanced product portfolio. For instance, in February 2019, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila) has received the U.S. FDA approval for marketing of triamterene and hydrochlorothiazide capsules, an anti-hypertensive drug. The product is widely prescribed for treatment of membranous nephropathy. The drug is also used for those patients whose demand is for the thiazide diuretic. The approval has paved the way for company to attain a lucrative growth in membranous nephropathy market.
Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) is the dominating player in the U.S. membranous nephropathy market. The other key players existing in the membranous nephropathy market includes Solco Healthcare, ALMATICA PHARMA LLC, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Novartis AG, Pfizer Inc., Viatris Inc., Avet Pharmaceuticals Inc., Lupin Pharmaceuticals, Inc., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Hikma Pharmaceuticals PLC, Accord Healthcare, Sun Pharmaceutical Industries Ltd., CareDx, Inc., Genentech, Inc. (a subsidiary of F. Hoffmann-La Roche Ltd), Azurity Pharmaceuticals, Inc., Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Strides Pharma Science Limited, Alembic Pharmaceuticals Limited, AbbVie Inc. among others.
Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.):
Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) is headquartered in New Jersey, U.S. The company is focused on development and production of affordable, high-quality generic drugs, innovative specialty pharmaceuticals and active pharmaceutical ingredients. The company provides various products under categories such as generic medicines, specialty medicines and biopharmaceuticals among which generic medicines is the market focused category.
For instance,
- In November 2016, Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.) announced the approval and the final stage of product launch in the United States of generic drug, tribenzor which is the combination of calcium channel blocker, angiotensin II blockers and thiazide diuretics. The product is used for the treatment of hypertension. The product approval has helped the company to enhance their product portfolio which will increase their revenues in coming future.
The company has presence across the U.S.
Pfizer Inc.:
Pfizer Inc. is headquartered in New York, U.S. and was founded in 1849. The company is focused on providing standards for quality, safety and value in the discovery, development and manufacturing of health care products including innovative medicines and vaccines. The company deals in multiple business segments such as biopharma, upjohn and consumer healthcare among which biopharma is the market focused segment. The company provides various products under categories such as internal medicine, inflammation & immunology, oncology, rare disease, vaccines and anti infectives among which internal medicine is the market focused category.
For instance,
- In July 2019, Pfizer Inc. acquired Array BioPharma Inc., a company focused on the discovery, development and commercialization of variety of medicines indicated for treatment of several kinds of diseases. The acquisition allowed the company to accelerate the research and development activities with involvement of company’s pipeline product portfolio. This acquisition helped the company to boost up the product portfolio and to earn a lucrative growth across several markets including membranous nephropathy market among others.
The company has presence across Europe, Middle East and Africa, Americas and Asia-Pacific. The company has various subsidiaries such as Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V. (Netherlands), Pfizer Australia Superannuation Pty Ltd (Australia), Pfizer Dominicana, S.A. (Dominican Republic), Pfizer Egypt S.A.E. (Egypt) among others.
Novartis AG:
Novartis AG is headquartered in Basel, Switzerland and was founded in 1996. The company focuses on innovating new solutions for various health care challenges. The company deals in multiple business segments such as innovative medicines and sandoz among which innovative medicines is the market focused segment. The company provides various products under categories such as cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience and respiratory among which cardiovascular, renal & metabolism is the market focused category.
For instance,
- In July 2014, Novartis AG along with the company business division Sandoz has announced the launch of the generic product, Diovan (valsartan) tablets which are used for the treatment of high blood pressure. The two generic products Diovan and Diovan HCT will be marketed in the U.S. by Novartis Pharmaceuticals Corporation. The product launch has helped the company to enhance their product portfolio as well as increased the revenue of the company as the generic drug is commercialized in the U.S.
The company has presence across Americas, Asia-Pacific, Europe and Middle East and Africa. The company has various subsidiaries such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium), Sandoz (China) Pharmaceutical (China) among others.
